26 February 2020 News
A Phase IIb study by researchers at the University of Manchester, UK, has demonstrated that P2X3 agonist gefapixant relieves refractory or unexplained chronic cough.
25 February 2020 News
Germany-based STADA has agreed to buy a portfolio of 15 consumer healthcare brands from GlaxoSmithKline (GSK) in European countries, including Germany, France, Poland, Italy, Russia, Spain and Switzerland.
10 February 2020 Analysis
Readers of Pharmaceutical Technology have been voting on how serious a threat the ongoing Wuhan coronavirus outbreak is to global health. To date there have been over 40,000 cases of...
12 December 2019 News
The US Food and Drug Administration (FDA) has agreed to review a supplemental biologics license application (sBLA) submitted by Novartis to seek approval for Xolair (omalizumab) to treat nasal polyps.
7 November 2019 Comment
The Glaxosmithkline headquarters office building in Brentford, London.
30 October 2019 News
Sanofi and Regeneron have received the European Commission (EC) approval for Dupixent (dupilumab) to treat adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP).
29 October 2019 Sponsored
Allergic rhinitis (AR) is a chronic inflammatory disease that affects the nasal mucosa. The condition is caused by immunoglobin E (IgE) – mediated early-phase and late-phase hypersensitivity responses. Common symptoms...
24 October 2019 Analysis
Four years after Orkambi was approved in the European Union, this life-saving drug will now be available to Cystic Fibrosis (CF) patients in England through the NHS. The reason for...
7 October 2019 News
The US Food and Drug Administration (FDA) has approved self-administration AstraZeneca's asthma drug Fasenra, a pre-filled, single-use auto-injector.